Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

Semenza GL.

Trends Pharmacol Sci. 2012 Apr;33(4):207-14. doi: 10.1016/j.tips.2012.01.005. Epub 2012 Mar 6. Review.

2.

Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.

Burroughs SK, Kaluz S, Wang D, Wang K, Van Meir EG, Wang B.

Future Med Chem. 2013 Apr;5(5):553-72. doi: 10.4155/fmc.13.17. Review.

3.

Targeting hypoxia for sensitization of tumors to radio- and chemotherapy.

Ghattass K, Assah R, El-Sabban M, Gali-Muhtasib H.

Curr Cancer Drug Targets. 2013 Jul;13(6):670-85. Review.

PMID:
23687923
4.

HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery.

Semenza GL.

Curr Pharm Des. 2009;15(33):3839-43. Review.

PMID:
19671047
5.

Development of HIF-1 inhibitors for cancer therapy.

Onnis B, Rapisarda A, Melillo G.

J Cell Mol Med. 2009 Sep;13(9A):2780-6. doi: 10.1111/j.1582-4934.2009.00876.x. Epub 2009 Aug 8. Review.

6.

Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.

Xia Y, Choi HK, Lee K.

Eur J Med Chem. 2012 Mar;49:24-40. doi: 10.1016/j.ejmech.2012.01.033. Epub 2012 Jan 24. Review.

PMID:
22305612
7.

Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer.

Agani F, Jiang BH.

Curr Cancer Drug Targets. 2013 Mar;13(3):245-51. Review.

PMID:
23297826
8.

Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.

Martínez-Sánchez G, Giuliani A.

J Exp Clin Cancer Res. 2007 Mar;26(1):39-50. Review.

PMID:
17550131
9.

Cancer therapeutic agents targeting hypoxia-inducible factor-1.

Wang R, Zhou S, Li S.

Curr Med Chem. 2011;18(21):3168-89. Review.

PMID:
21671859
10.

Cancer therapy by targeting hypoxia-inducible factor-1.

Li Y, Ye D.

Curr Cancer Drug Targets. 2010 Nov;10(7):782-96. Review.

PMID:
20578983
11.

The role of hypoxia inducible factor-1 in cell metabolism--a possible target in cancer therapy.

Bel Aiba RS, Dimova EY, Görlach A, Kietzmann T.

Expert Opin Ther Targets. 2006 Aug;10(4):583-99. Review.

PMID:
16848694
12.

Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.

Wilczynski J, Duechler M, Czyz M.

Arch Immunol Ther Exp (Warsz). 2011 Aug;59(4):301-7. doi: 10.1007/s00005-011-0132-3. Epub 2011 May 28. Review.

PMID:
21625847
13.

Evaluation of HIF-1 inhibitors as anticancer agents.

Semenza GL.

Drug Discov Today. 2007 Oct;12(19-20):853-9. Epub 2007 Sep 18. Review.

PMID:
17933687
14.

Role of hypoxia-inducible factors in breast cancer metastasis.

Gilkes DM, Semenza GL.

Future Oncol. 2013 Nov;9(11):1623-36. doi: 10.2217/fon.13.92. Review.

15.

Hypoxia and hypoxia-inducible factors: master regulators of metastasis.

Lu X, Kang Y.

Clin Cancer Res. 2010 Dec 15;16(24):5928-35. doi: 10.1158/1078-0432.CCR-10-1360. Epub 2010 Oct 20. Review.

16.

HIF-1 signaling in drug resistance to chemotherapy.

Warfel NA, El-Deiry WS.

Curr Med Chem. 2014;21(26):3021-8. Review.

PMID:
24735366
17.

[Research progress of hypoxia-inducible factor 1 inhibitors against tumors].

Niu F, Li Y, Lai FF, Chen XG.

Yao Xue Xue Bao. 2014 Jun;49(6):832-6. Review. Chinese.

PMID:
25212028
18.

Hypoxia inducible factor-1: a novel target for cancer therapy.

Belozerov VE, Van Meir EG.

Anticancer Drugs. 2005 Oct;16(9):901-9. Review.

PMID:
16162966
19.

HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention.

Monti E, Gariboldi MB.

Curr Mol Pharmacol. 2011 Jan;4(1):62-77. Review.

PMID:
20958262
20.

Role of hypoxia in the hallmarks of human cancer.

Ruan K, Song G, Ouyang G.

J Cell Biochem. 2009 Aug 15;107(6):1053-62. doi: 10.1002/jcb.22214. Review.

PMID:
19479945

Supplemental Content

Support Center